Wilson S H, Best P J, Lerman L O, Holmes D R, Richardson D M, Lerman A
Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA.
Cardiovasc Res. 1999 Dec;44(3):601-7. doi: 10.1016/s0008-6363(99)00225-4.
The F2-isoprostanes are a family of novel prostaglandin isomers and a stable product of in vivo oxidative stress. 8-epi-prostaglandinF2 alpha, a member of this isoprostane family, is a vasoconstrictor and its local release may contribute to the abnormal vasomotor tone associated with hypercholesterolemia. We therefore aimed to outline the role of 8-epi-prostaglandinF2 alpha as a coronary vasoconstrictor in experimental hypercholesterolemia.
Pigs were randomized to two experimental groups (each n = 9): normal (N) and high cholesterol (HC) diet. To determine the vasoconstrictive effects of 8-epi-prostaglandinF2 alpha in vitro, doses from 10(-9) to 10(-5) M were used to constrict coronary epicardial rings. Plasma total and LDL cholesterol levels were significantly higher in the HC group compared with the N group (P < 0.005) as were plasma 8-epi-prostaglandinF2 alpha levels (P < 0.001). 8-epi-prostaglandinF2 alpha immunoreactivity was present in the vessel wall in both groups. Normal vessels with intact endothelium (n = 8 rings) contracted to 8-epi-prostaglandinF2 alpha (maximal contraction 15.5 +/- 8.74%). In the HC group, rings with intact endothelium had a greater contractile response to 8-epi-prostaglandinF2 alpha compared to normals (72.3 +/- 7.9%; n = 8; P < 0.0001). This was reversed by preincubation with NOR-3, a NO donor (maximal contraction 6.7 +/- 1.56%; n = 5; P < 0.0001). Enhanced contraction in normal vessels occurred with endothelial denudation (98.4 +/- 3.56%; n = 6; P < 0.0001) and with preincubation of the endothelium-intact rings with L-NMMA (N-monomethyl-L-arginine), an NO synthase inhibitor (85.5 +/- 10.3%, n = 6, P < 0.001). The enhanced contraction seen with hypercholesterolemia did not occur with other prostanoid vasoconstrictors.
Experimental hypercholesterolemia leads to a significant increase in 8-epi-prostaglandinF2 alpha levels in addition to enhanced 8-epi-prostaglandinF2 alpha-induced coronary vasoconstriction, in vitro. These findings support a role for the F2-isoprostanes in the regulation of coronary vasomotor tone in pathophysiologic states.
F2-异前列腺素是一类新型前列腺素异构体,是体内氧化应激的稳定产物。8-表-前列腺素F2α是该异前列腺素家族的成员之一,是一种血管收缩剂,其局部释放可能导致与高胆固醇血症相关的异常血管舒缩张力。因此,我们旨在概述8-表-前列腺素F2α作为实验性高胆固醇血症中冠状动脉收缩剂的作用。
将猪随机分为两个实验组(每组n = 9):正常(N)饮食组和高胆固醇(HC)饮食组。为了确定8-表-前列腺素F2α在体外的血管收缩作用,使用10(-9)至10(-5) M的剂量收缩冠状动脉心外膜环。与N组相比,HC组的血浆总胆固醇和低密度脂蛋白胆固醇水平显著更高(P < 0.005),血浆8-表-前列腺素F2α水平也是如此(P < 0.001)。两组的血管壁中均存在8-表-前列腺素F2α免疫反应性。内皮完整的正常血管(n = 8个环)对8-表-前列腺素F2α产生收缩反应(最大收缩率15.5 +/- 8.74%)。在HC组中,与正常组相比,内皮完整的环对8-表-前列腺素F2α的收缩反应更大(72.3 +/- 7.9%;n = 8;P < 0.0001)。用NO供体NOR-3预孵育可逆转这种情况(最大收缩率6.7 +/- 1.56%;n = 5;P < 0.0001)。正常血管在内皮剥脱时(98.4 +/- 3.56%;n = 6;P < 0.0001)以及用NO合酶抑制剂L-NMMA(N-单甲基-L-精氨酸)预孵育内皮完整的环时(85.5 +/- 10.3%,n = 6,P < 0.001)会出现增强的收缩。高胆固醇血症时出现的增强收缩在其他前列腺素血管收缩剂作用下未出现。
实验性高胆固醇血症除了增强8-表-前列腺素F2α诱导的冠状动脉收缩外,还导致8-表-前列腺素F2α水平显著升高。这些发现支持F2-异前列腺素在病理生理状态下调节冠状动脉血管舒缩张力中的作用。